MARKET

KLRS

KLRS

Kalaris Therapeutics Inc
NASDAQ
5.26
+0.43
+8.90%
Opening 10:59 05/14 EDT
OPEN
4.900
PREV CLOSE
4.830
HIGH
5.39
LOW
4.840
VOLUME
78.88K
TURNOVER
--
52 WEEK HIGH
11.88
52 WEEK LOW
2.140
MARKET CAP
125.15M
P/E (TTM)
-2.3754
1D
5D
1M
3M
1Y
5Y
1D
Kalaris Therapeutics Price Target Cut to $25.00/Share From $26.00 by Citizens
Dow Jones · 1d ago
Kalaris Therapeutics Is Maintained at Market Outperform by Citizens
Dow Jones · 1d ago
Citizens Maintains Market Outperform on Kalaris Therapeutics, Lowers Price Target to $25
Benzinga · 1d ago
Analysts Offer Insights on Healthcare Companies: Kalaris Therapeutics (KLRS), Zentalis Pharmaceuticals (ZNTL) and Bristol-Myers Squibb (BMY)
TipRanks · 1d ago
Kalaris Therapeutics price target lowered to $25 from $26 at Citizens
TipRanks · 1d ago
Analysts Are Bullish on Top Healthcare Stocks: Immunome (IMNM), Kalaris Therapeutics (KLRS)
TipRanks · 1d ago
Kalaris Therapeutics, Inc. GAAP EPS of -$0.46
Seeking Alpha · 1d ago
Kalaris Therapeutics reports Q1 EPS (46c), consensus (52c)
TipRanks · 1d ago
More
About KLRS
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).

Webull offers Kalaris Therapeutics Inc stock information, including NASDAQ: KLRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KLRS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KLRS stock methods without spending real money on the virtual paper trading platform.